Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

NCT02698111 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate policy adjustments

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Donafenib

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd